A small molecule drug that activates a component of the innate immune system could play a role in enhancing radiation therapy for the treatment of cancers, according to a study published in Nature Communications on 19 April 2021. The study, conducted by Yale University in the US and F-star Therapeutics Ltd, co-located in the UK and US, looked at the role of STING (stimulator of interferon genes) in regulating tumour cell survival.
